Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator ozanimod in the treatment of relapsing forms of multiple sclerosis.
Ook interessant voor je
Reageer